Pharmathene Discussion of Avecia Acquisition Conference Call Transcript - Thomson StreetEvents

Pharmathene Discussion of Avecia Acquisition Conference Call Transcript

Pharmathene Discussion of Avecia Acquisition Conference Call Transcript - Thomson StreetEvents
Pharmathene Discussion of Avecia Acquisition Conference Call Transcript
Published Mar 20, 2008
7 pages (3367 words) — Published Mar 20, 2008
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALT.OQ earnings conference call or presentation 20-Mar-08 8:30pm GMT

  
Brief Excerpt:

...Operator Good day ladies and gentlemen and welcome to the PharmAthene-Avecia acquisition conference call. My name is Denise and I will be your coordinator for today's conference. At this time, all participants are in listen-only mode. We will be conducting a question and answer session towards the end of this conference. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded for replay purposes. I would now like to turn the presentation over to your host for today's call, Ms. Stacey Jurchison, Director of Corporate Communications. Please proceed, ma'am. Stacey Jurchison ...

  
Report Type:

Transcript

Source:
Company:
Altimmune Inc
Ticker
ALT.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Stefan Loren - Perceptive Advisors, LLC - Analyst : Thank you very much, good afternoon and thanks for taking the call. I was just wondering if you could touch a little bit on the thought behind the multi-approach you now have going forward to anthrax vis-a-vis Valortim and the RFP at this point. Can those coexist well together? Do you think it gives you a nice advantage going forward? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.


Question: Stefan Loren - Perceptive Advisors, LLC - Analyst : Thank you. I'll jump back into the queue. I've got one more question.


Question: Christopher Brock - Advanced Equities - Analyst : I don't know if this is public knowledge or not, but how many other companies have submitted RFPs for the award -- for the anthrax award in, I think, you said it was May?


Question: Christopher Brock - Advanced Equities - Analyst : Okay, great. Congratulations on the acquisition. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.


Question: Stefan Loren - Perceptive Advisors, LLC - Analyst : Thank you. Just wanted to follow up on the UK assets that you're getting. Obviously, you're going to be bringing some scientists on board, it sounds like. But can you give us a little bit more specific on that? And then, comment -- the dollar hasn't been as strong as, I guess, many of us would like it to be, what is this going to do the burn rate going forward?

Table Of Contents

Pharmathene Q3 2008 Earnings Conference Call Transcript – 2008-11-13 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 13-Nov-08 9:30pm GMT

Pharmathene at UBS Global Life Sciences Conference Transcript – 2008-09-25 – US$ 54.00 – Edited Transcript of ALT.OQ presentation 25-Sep-08 5:30pm GMT

Pharmathene Q2 2008 Earnings Conference Call Transcript – 2008-08-12 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 12-Aug-08 8:30pm GMT

Pharmathene Q1 2008 Earnings Conference Call Transcript – 2008-05-13 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 13-May-08 8:30pm GMT

Pharmathene Q4 2007 Earnings Conference Call Transcript – 2008-03-31 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 31-Mar-08 8:30pm GMT

PharmAthene, Inc at BIO CEO & Investor Conference Transcript – 2008-02-13 – US$ 54.00 – Edited Transcript of ALT.OQ presentation 13-Feb-08 5:30pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Pharmathene Discussion of Avecia Acquisition Conference Call Transcript" Mar 20, 2008. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Pharmathene-Discussion-of-Avecia-Acquisition-Conference-Call-T1793630>
  
APA:
Thomson StreetEvents. (2008). Pharmathene Discussion of Avecia Acquisition Conference Call Transcript Mar 20, 2008. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Pharmathene-Discussion-of-Avecia-Acquisition-Conference-Call-T1793630>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.